Recently, a multicenter study published in the *Journal of Clinical Oncology* demonstrated that liquid biopsy-based multi-cancer early detection (MCED) technology can identify over 50 cancer types in asymptomatic individuals, with an overall sensitivity of 51.5% and specificity of 99.5%. Notably, early-stage (I-II) detection rates for high-incidence cancers such as lung, colorectal, and breast cancer were more than twofold higher compared to traditional tumor markers. The study, conducted jointly by multiple cancer centers in the United States with a sample size exceeding 12,000 participants, marks a critical step forward for liquid biopsy in the field of cancer early screening.
Liquid biopsy enables non-invasive, convenient capture of early cancer signals by analyzing biomarkers in blood, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes. Compared to tissue biopsy, it offers minimal invasiveness, high repeatability, and real-time reflection of tumor genomic alterations. Currently, this technology has been approved for clinical auxiliary diagnosis in the United States and several European countries, and multiple medical institutions in China are also accelerating its adoption.
Background and Significance
Traditional cancer screening relies on imaging and endoscopy, which have limited sensitivity for early微小 lesions and are restricted to single cancer types. Liquid biopsy, with its advantage of "one blood draw for multiple cancers," provides a novel paradigm for cancer early screening. The aforementioned study further confirms the feasibility of MCED in real-world populations, particularly filling gaps for cancers lacking standard screening methods, such as pancreatic and ovarian cancer. However, the industry also notes that liquid biopsy still requires optimization in terms of positive predictive value, patient follow-up pathways, and cost control, and more prospective data are needed before large-scale population screening can be realized.
Significance for International Patients
For international patients, advances in liquid biopsy technology mean opportunities for earlier cancer detection, especially in cases of metastatic tumors with unknown primary sites or individuals who cannot tolerate tissue biopsy, where liquid biopsy serves as an effective alternative. However, interpretation of test results requires correlation with imaging and clinical history, and technical parameters vary across platforms. Patients must choose certified laboratories and standardized clinical processes. Additionally, cross-border medical care involves sample transportation, report translation, and subsequent treatment coordination, necessitating professional organizational support.
How MedBridge Can Help
MedBridge Shanghai, as a cross-border medical platform, has established partnerships with multiple CLIA-certified liquid biopsy laboratories and partner hospitals, offering international patients one-stop services including MCED testing appointments, international sample logistics, bilingual report interpretation, and follow-up specialist care coordination. Our medical services team assesses testing suitability based on individual and family medical history and provides cost estimates to ensure a transparent process. If you wish to learn more about the specific applications of liquid biopsy in cancer early screening, feel free to contact us for personalized advice.
Related reading: Overview of Partner Hospitals in Shanghai